請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72005
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳培哲(Pei-Jer Chen) | |
dc.contributor.author | Jau-Hau Horng | en |
dc.contributor.author | 洪昭皓 | zh_TW |
dc.date.accessioned | 2021-06-17T06:18:46Z | - |
dc.date.available | 2021-02-23 | |
dc.date.copyright | 2021-02-23 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-10-12 | |
dc.identifier.citation | 1. Lok AS, Zoulim F, Dusheiko G, Ghany MG (2017) Hepatitis B cure: From discovery to regulatory approval. Journal of Hepatology 67(4):847-861. 2. Iloeje UH, et al. (2007) Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection. Clinical Gastroenterology and Hepatology 5(8):921-931. 3. Yapali S, Talaat N, Lok AS (2014) Management of hepatitis B: our practice and how it relates to the guidelines. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 12(1):16-26. 4. Wherry EJ (2011) T cell exhaustion. Nature Immunology 12(6):492-499. 5. Wherry EJ Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15(8):486-499. 6. Sen DR, et al. (2016) The epigenetic landscape of T cell exhaustion. Science 354(6316):1165. 7. Boni C, et al. (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. Journal of virology 81(8):4215-4225. 8. Bengsch B, Martin B, Thimme R (2014) Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol 61(6):1212-1219. 9. Schuch A, et al. (2019) Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. Gut 68(5):905-915. 10. Burton AR, et al. (2018) Circulating and intrahepatic antiviral B cells are defective in hepatitis B. The Journal of clinical investigation 128(10):4588-4603. 11. Ma Z, Zhang E, Gao S, Xiong Y, Lu M (2019) Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response. Front Immunol 10:2308-2308. 12. Mueller SN Ahmed R (2009) High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 106(21):8623-8628. 13. Utzschneider DT, et al. (2016) High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. The Journal of experimental medicine 213(9):1819-1834. 14. Tay SS, et al. (2014) Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses. Proc Natl Acad Sci U S A 111(25):E2540-2549. 15. Martinez GJ, et al. (2015) The Transcription Factor NFAT Promotes Exhaustion of Activated CD8+ T Cells. Immunity 42(2):265-278. 16. Alfei F, et al. (2019) TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. Nature 571(7764):265-269. 17. Khan O, et al. (2019) TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571(7764):211-218. 18. Chen L Flies DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13(4):227-242. 19. Dembek C, Protzer U, Roggendorf M (2018) Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination. Current opinion in virology 30:58-67. 20. Lucifora J, et al. (2011) Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 55(5):996-1003. 21. van Breugel PC, et al. (2012) Hepatitis B virus X protein stimulates gene expression selectively from extrachromosomal DNA templates. Hepatology (Baltimore, Md.) 56(6):2116-2124. 22. Mueller H, et al. (2018) A novel orally available small molecule that inhibits hepatitis B virus expression. Journal of Hepatology 68(3):412-420. 23. Niu C, et al. (2017) The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection. PloS one 12(1):e0169648. 24. Maini MK Pallett LJ (2018) Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. The lancet. Gastroenterology hepatology 3(3):192-202. 25. King TH, et al. (2014) A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PloS one 9(7):e101904. 26. Boni C, et al. (2019) Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. Gastroenterology 157(1):227-241.e227. 27. Hu J, Lin YY, Chen PJ, Watashi K, Wakita T (2019) Cell and Animal Models for Studying Hepatitis B Virus Infection and Drug Development. Gastroenterology 156(2):338-354. 28. Guidotti LG, et al. (1994) Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A 91(9):3764-3768. 29. Shimizu Y, Guidotti LG, Fowler P, Chisari FV (1998) Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. Journal of immunology (Baltimore, Md. : 1950) 161(9):4520-4529. 30. Lv S, et al. (2014) Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection. Hepatology (Baltimore, Md.) 59(2):385-394. 31. Zhao HJ, et al. (2019) Poly I:C-based rHBVvac therapeutic vaccine eliminates HBV via generation of HBV-specific CD8(+) effector memory T cells. Gut 68(11):2032-2043. 32. Kosinska AD, et al. (2019) Synergy of therapeutic heterologous prime-boost hepatitis B vaccination with CpG-application to improve immune control of persistent HBV infection. Scientific reports 9(1):10808. 33. Huang LR, Wu HL, Chen PJ, Chen DS (2006) An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A 103(47):17862-17867. 34. Chou HH, et al. (2015) Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc Natl Acad Sci U S A 112(7):2175-2180. 35. Crispe IN (2009) The liver as a lymphoid organ. Annual review of immunology 27:147-163. 36. Thomson AW Knolle PA (2010) Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 10(11):753-766. 37. Bertolino P, Trescol-Biémont MC, Rabourdin-Combe C (1998) Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. European journal of immunology 28(1):221-236. 38. Knolle PA, et al. (1999) Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells. Gastroenterology 116(6):1428-1440. 39. Viñas O, et al. (2003) Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology (Baltimore, Md.) 38(4):919-929. 40. Bénéchet AP, et al. (2019) Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature 574(7777):200-205. 41. Holz LE, et al. (2012) Naïve CD8 T cell activation by liver bone marrow-derived cells leads to a 'neglected' IL-2low Bimhigh phenotype, poor CTL function and cell death. J Hepatol 57(4):830-836. 42. Gehring AJ Protzer U (2019) Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology 156(2):325-337. 43. Huang LR, et al. (2013) Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol 14(6):574-583. 44. Cebula M, et al. (2017) TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall. Molecular therapy : the journal of the American Society of Gene Therapy 25(10):2289-2298. 45. Klinman DM (2004) Immunotherapeutic uses of CpG oligodeoxynucleotides. Nature Reviews Immunology 4(4):249-259. 46. Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nature Reviews Drug Discovery 5(6):471-484. 47. Liao CW, et al. (2005) Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer research 65(19):9089-9098. 48. Wu LL, et al. (2019) Lymphocyte Antigen 6 Complex, Locus C(+) Monocytes and Kupffer Cells Orchestrate Liver Immune Responses Against Hepatitis B Virus in Mice. Hepatology (Baltimore, Md.) 69(6):2364-2380. 49. Rai D, Pham NL, Harty JT, Badovinac VP (2009) Tracking the total CD8 T cell response to infection reveals substantial discordance in magnitude and kinetics between inbred and outbred hosts. Journal of immunology (Baltimore, Md. : 1950) 183(12):7672-7681. 50. Ginhoux F Jung S (2014) Monocytes and macrophages: developmental pathways and tissue homeostasis. Nature Reviews Immunology 14(6):392-404. 51. Jakubzick CV, Randolph GJ, Henson PM (2017) Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol 17(6):349-362. 52. Claassen I, Van Rooijen N, Claassen E (1990) A new method for removal of mononuclear phagocytes from heterogeneous cell populations in vitro, using the liposome-mediated macrophage 'suicide' technique. Journal of immunological methods 134(2):153-161. 53. Qian Q, Jutila MA, Van Rooijen N, Cutler JE (1994) Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. Journal of immunology (Baltimore, Md. : 1950) 152(10):5000-5008. 54. Zhu J, Chen H, Huang X, Jiang S, Yang Y (2016) Ly6C(hi) monocytes regulate T cell responses in viral hepatitis. JCI insight 1(17):e89880. 55. Cividalli A, et al. (2000) Schedule dependent toxicity and efficacy of combined gemcitabine/paclitaxel treatment in mouse adenocarcinoma. Journal of cancer research and clinical oncology 126(8):461-467. 56. Viola A Lanzavecchia A (1996) T cell activation determined by T cell receptor number and tunable thresholds. Science 273(5271):104-106. 57. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN (1996) Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4(6):565-571. 58. Rivino L, et al. (2018) Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. The Journal of clinical investigation 128(2):668-681. 59. Lin YJ, Wu HL, Chen DS, Chen PJ (2012) Hepatitis B virus nucleocapsid but not free core antigen controls viral clearance in mice. Journal of virology 86(17):9266-9273. 60. Kornyeyev D, et al. (2019) Spatiotemporal Analysis of Hepatitis B Virus X Protein in Primary Human Hepatocytes. Journal of virology 93(16). 61. Sitia G, et al. (2004) MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. The Journal of clinical investigation 113(8):1158-1167. 62. Sitia G, et al. (2011) Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS pathogens 7(6):e1002061. 63. Guilliams M, Mildner A, Yona S (2018) Developmental and Functional Heterogeneity of Monocytes. Immunity 49(4):595-613. 64. Movita D, et al. (2015) Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct. Journal of virology 89(9):4809-4817. 65. De Koker S, et al. (2017) Inflammatory monocytes regulate Th1 oriented immunity to CpG adjuvanted protein vaccines through production of IL-12. Scientific reports 7(1):5986. 66. Nguyen KB, et al. (2002) Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. Journal of immunology (Baltimore, Md. : 1950) 169(8):4279-4287. 67. Li J, et al. (2015) Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection. Vaccine 33(35):4247-4254. 68. Lee BO, et al. (2009) Interaction of the hepatitis B core antigen and the innate immune system. Journal of immunology (Baltimore, Md. : 1950) 182(11):6670-6681. 69. Bian Y, et al. (2017) Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. Hepatology (Baltimore, Md.) 66(4):1067-1082. 70. Huang LR, et al. (2012) Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice. Gastroenterology 142(7):1447-1450.e1443. 71. Tzeng HT, et al. (2012) PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PloS one 7(6):e39179. 72. Hoa PT, et al. (2009) Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrobial agents and chemotherapy 53(12):5134-5140. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72005 | - |
dc.description.abstract | B型肝炎病毒是造成慢性B型肝炎感染的主因,目前在全世界約有2億5千萬的慢性B型肝炎感染者,但目前醫學上仍缺乏有效的根治方法,因此找尋有效的療法是目前的當務之急。目前開發中的療法中,慢性B型肝炎的免疫治療被寄予厚望,其中治療性疫苗已經研究超過20年,但目前仍未能在臨床試驗成功。因此,在合適的動物模式研究治療性疫苗及其相關的免疫機轉是有必要的。B型肝炎病毒的免疫治療之所以困難的主因是由於抗B型肝炎病毒T細胞的耗竭(T cell exhaustion)現象,當耗竭現象發生時,抗原特異性的T細胞的毒殺及分泌細胞激素的功能會大幅減弱,因而無法順利清除入侵的病原。目前科學上已經知道T細胞受體接受大量且持續的抗原暴露是產生耗竭現象的重要因子。由於目前研發中的B型肝炎治療性疫苗大多使用病毒的結構蛋白,例如表面或核心抗原,但這些抗原在肝臟細胞內表現量較高,慢性B型肝炎病人的表面(HBs)或核心抗原(HBc)的毒殺型T細胞在長期抗原暴露下,已經有嚴重的耗竭現象。我們的假說是X蛋白(HBx)特異性的T細胞因在宿主的表現量,對抗原的暴露量遠少於其他結構蛋白,因而能夠避開或減緩T細胞的耗竭現象,並更容易被治療性疫苗刺激重新恢復功能。 HBx目前免疫原性以及作為治療性疫苗使用的數據較少,為了解HBx的免疫原性及其作為治療性疫苗的潛力,我們選擇HBx作為主要的抗原,並且輔以強力的免疫佐劑CpG-ODN作為測試用的治療性疫苗。為了在動物模式研究此疫苗之效力,我們選用先前建立之基於高壓流體注射法的小鼠慢性B型肝炎病毒帶原模型。我們將從病人身上的B型肝炎病毒序列複製到pAAV重組質體上,再透過高壓流體注射法轉染至CBA/CaJ品系小鼠的肝臟細胞,此時B型肝炎病毒質體能在小鼠體內穩定表現超過6個月。我們選用血清表面抗原效價>500IU/mL並維持超過4周以上的小鼠來模擬人類的慢性B型肝炎,並注射前述的HBx疫苗來研究其抗HBV的效果及其免疫原性。我們以酶聯免疫吸附斑點法(ELISpot)分析脾臟內抗原特異性T細胞的產生。血液中的病毒量以HBs的酵素免疫分析法及HBV-DNA的定量即時聚合酶鏈鎖反應(Q-PCR)評估。肝臟中的病毒量以HBc的西方墨點法(Western blotting)及免疫組織化學(immunohistochemistry)分析。此外,我們也針對血液或肝臟內的免疫細胞,經分離程序後進行流式細胞儀的定量分析。 我們的研究結果顯示,在未受HBV轉染的小鼠,注射HBx疫苗3次後,脾臟能夠產生HBx特異性的T細胞,並且經過後續HBV轉染後,血清中病毒量有顯著的降低。另一方面,對HBV帶原小鼠給予3次HBx疫苗後,血清在3周後即無法偵測到病毒,實驗終點時分析肝臟內的病毒抗原亦達到完全消失,同時 HBx疫苗亦能夠在HBV帶原小鼠引發系統性的CD4及CD8 T細胞免疫力。在治療性疫苗注射後以流式細胞儀分析肝臟淋巴球組成,我們發現肝臟內有疫苗誘導的T細胞累積。治療成功的小鼠若於一個月後接受第二次HBV轉染,第二次注射後的血清病毒量與只打CpG佐劑的小鼠相比有顯著的下降,顯示HBx疫苗能產生持續的免疫力。此外,我們也發現疫苗抗原的選擇對其療效有顯著的影響:比較以HBx及HBc作為治療性疫苗的抗原時,僅HBx能清除小鼠血液中的病毒抗原並產生系統性的抗原特異性T細胞。與HBc相比,HBx疫苗注射亦能在肝臟造成更多的單核白血球(monocytes)累積。在疫苗治療的期間若以藥物移除不同的肝臟骨髓系細胞(myeloid cell)子群體,影響疫苗治療效果的程度也不同。若僅移除巨噬細胞類,包含monocyte衍生的巨噬細胞(Monocyte-derived Macrophage)以及庫式細胞(Kupffer cells),僅能暫時抑制病毒清除的作用,但最終仍會達到清除。若連炎症性單核球(Inflammatory monocyte)一併移除,則病毒清除的作用將受到大幅度的影響,最終造成病毒清除失敗。 我們的研究展示了HBx作為慢性B型肝炎治療性疫苗的潛力以及不同肝臟內骨髓系細胞對疫苗清除病毒的重要性。適當的抗原設計以及透過適當的佐劑調節肝臟內免疫微環境可能是發展下一代慢性B型肝炎治療性疫苗的關鍵。 | zh_TW |
dc.description.abstract | Background and Hypothesis: Hepatitis B virus (HBV) persistently infects about 250 million people worldwide, and a curative treatment remains an unmet medical need. Among many approaches to treat chronic hepatitis B (CHB), therapeutic vaccines have been developed for two decades, but none have yielded promising results in clinical trials. Therefore, dissection of HBV clearance mechanisms during therapeutic vaccination in appropriate models, which could give rise to new curative therapies, is urgently needed. Growing evidence indicates that prolonged and intensive exposure of antigen-specific T cells to viral antigens is a major cause of T cell exhaustion and decreases anti-HBV immunity efficacy of therapeutic vaccination. Hence, we propose that in chronic HBV carriers, antigen specific T cell targeting low-level expressing viral proteins may be less exhausted and their antiviral function could be rejuvenated through therapeutic vaccination. Methods: HBV X protein (HBx) is expressed at low levels during natural infection, and the understanding of its immunogenicity and potential in therapeutic CHB vaccines is limited. We selected HBx as the major antigen, and a robust adjuvant CpG-ODN-1826, was added to boost antigen’s immunogenicity. To test the therapeutic potential of HBx based therapeutic vaccine in an immunocompetent animal model, HBV genome sequences from CHB patients were cloned into a pAAV plasmid backbone and transfected into immunocompetent mouse hepatocytes through hydrodynamic injection. Mice carrying >500 IU/mL serum HBV surface antigen (HBs) for more than 4 weeks were considered HBV carriers mimicking human CHB and received 3 doses of weekly HBx vaccine by subcutaneous immunization. Serum HBV clearance was evaluated by monitoring serum HBs and HBV-DNA titers. Residual HBV in the liver was evaluated by western blotting for HBV core antigen. The splenic antigen-specific T cell response was quantified by a 15-mer overlapping peptide-stimulated interferon-γ enzyme-linked immunospot assay. Blood and hepatic immune cells were quantified by flow cytometric analysis. Results: Naïve CBA/CaJ mice immunized with HBx-based vaccine shows the induction of HBx specific T cell immunity and protected mice from HBV exposure. In HBV carrier mice, HBx vaccination results in significant HBs and HBV-DNA elimination. The vaccine induced systemic HBx-specific CD4+ and CD8+ T cell responses, and liver CD8+ T cell influx was also observed. The protective effect persisted for at least 30 days without additional booster immunization. The antigen selection largely affects the potency of vaccine-mediated HBV clearance. Compare with HBx, HBV core antigen (HBc) serving as vaccine antigen cannot induce systemic T cell immunity or hepatic HBV clearance. HBx vaccine also induces higher hepatic monocyte infiltration than HBc, suggesting that the hepatic myeloid cell infiltration may be important to hepatic viral clearance. Different infiltrating myeloid cell subsets, each with distinctive roles during vaccine-mediated HBV clearance, were found in mouse liver after HBx vaccination. During vaccine therapy, Ly6Chigh monocyte derived macrophage (MDM) depletion resulted in sustained HBV clearance inhibition. In contrast, phagocytic monocyte-derived macrophage and Kupffer cell elimination resulted in only transient inhibition of vaccine-induced HBV clearance. Conclusions: We report the potential of HBx protein as a major immunogen in an HBV therapeutic vaccine in an HBV-persistent animal model. Appropriate antigen selection significantly affects the efficacy of therapeutic vaccine. Among the vaccine-induced hepatic myeloid cell subsets, the Ly6Chigh MDMs may have unique functions to promote hepatic T cell immunity and viral clearance. Appropriate antigen design and the liver resident myeloid cell microenvironment may be the keys to developing next-generation therapeutic HBV vaccines. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:18:46Z (GMT). No. of bitstreams: 1 U0001-1210202013475600.pdf: 2341716 bytes, checksum: 19dfda3ceac35e209437d6472cbbf6c2 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 誌謝 i 中文摘要: ii Abstract v 1.1 Chronic hepatitis B virus infections 2 1.2 HBV specific T cell exhaustion and CHB immune therapy 2 1.3 The HBV X protein (HBx) and its potential use in therapeutic vaccine 4 1.4 Animal models to mimic chronic hepatitis B virus infection 6 1.5 The liver immune environment and immune therapy 8 Materials and Methods 11 2.1 Experiment animals 12 2.2 The pAAV-HBV plasmid constructs 12 2.3 The hydrodynamic HBV transfection mouse model 13 2.4 Preparation and administration protocol for the vaccine formulation 13 2.5 Extraction and quantification of serum and liver HBV-DNA 14 2.6 Serum viral biomarker analysis 15 2.7 Western blotting 15 2.8 Immunohistochemistry 16 2.9 IFN-γ enzyme-linked immunospot (ELISpot) assay 17 2.10 Mouse liver lymphoid and myeloid cell isolation 18 2.11 Mouse peripheral blood mononuclear cell isolation and the complete blood count 20 2.12 Flow cytometry analysis 20 2.13 Administration of monocyte-depleting drugs 21 2.14 Statistical analyses 22 Results 23 3.1 Serum HBs persistent in CBA/CaJ mouse after transfected with different HBV genotype plasmid 24 3.2 The immunogenicity of HBx based vaccine in naïve CBA/CaJ mice 24 3.3 Prophylactic immunization by HBx vaccine reduced viral titers after HDI HBV challenge 25 3.4 Therapeutic HBx vaccination removes both HBV antigen and viral DNA from carrier mice 27 3.5 Therapeutic HBx vaccination removes HBV in genotype independent fashion 29 3.6 TVGV-HBx vaccination induces a systemic HBx-specific T cell response in the context of HBV viremia 29 3.7 Therapeutic HBx vaccine induced CD8+ T cell accumulates in the liver 30 3.8 Therapeutic HBx vaccination provides long-lasting protective effect to second HBV exposure 31 3.9 HBc and HBx, as immunogens, induce distinct types of immunity against persistent HBV 32 3.10 Therapeutic HBx vaccination induces monocytes mobilization to blood stream 34 3.11 Different monocyte depletion drugs lead to distinct impacts to HBx vaccination induced HBV clearance 37 3.12 CL and GEM treatments alter the liver immune environment after HBx vaccination and impacts HBV clearance 39 Discussion 41 4.1 The potential of HBx as an immunogen of therapeutic HBV vaccine 42 4.2 The significance and possible mechanism of CpG-ODN mediated hepatic monocyte derived macrophage recruitment for hepatic HBV clearance 44 4.3 The selection of immunogen may affect innate immunity in myeloid cells 47 4.4 The HBx vaccine does not restore HBV specific humoral immunity 48 4.5 The limitation of HBV animal models and future prospects 49 References 52 Figures 59 Figure 1. The schematic diagram of RAP1-HBx, RAP1-E7 and rHBx composition 60 Figure 2. CBA/CaJ mice allows serum HBs persistent in HBV genotype independent manner. 61 Figure 3. TVGV-HBx immunization induces HBx specific T cell immunity in naïve CBA/CaJ mice. 62 Figure 4. TVGV-HBx exerts a protective function against hydrodynamic HBV exposure in persistence-prone CBA/CaJ mice. 63 Figure 5. TVGV-HBx exerts therapeutic function in HBV (genotype C) carrier mice. 65 Figure 6. TVGV-HBx exerts therapeutic function in HBV (genotype A, B and D) carrier mice. 66 Figure 7. TVGV-HBx vaccination induces systemic HBx specific T cell immunity in carrier mice. 67 Figure 8. TVGV-HBx vaccination induced CD8+ T cell influx the liver. 69 Figure 9. Therapeutic TVGV-HBx vaccination provides post-cure protection effect to second HBV exposure. 70 Figure 10. Determine the minimal effective dose of TVGV-HBx vaccine. 71 Figure 11. HBc and HBx induce distinct types of immune response while serving as therapeutic vaccine immunogen. 72 Figure 12. TVGV-HBx administration induces monocyte mobilization and the efficiency of drug-mediated monocyte depletion. 75 Figure 13. Different monocyte depletion drugs lead to distinct impact to TVGV-HBx induced HBV clearance. 76 Figure 14. Monocyte depletion drugs reduce hepatic MDMs infiltration. 78 Figure 15. Schematic diagrams of the hypothetic models 80 Appendix 81 Lists of abbreviations 82 | |
dc.language.iso | en | |
dc.title | 基於HBV X蛋白之治療性疫苗於慢性B型肝炎病毒帶原小鼠之療效及相關免疫機轉研究 | zh_TW |
dc.title | Efficacy and Mechanism of the HBV X protein based therapeutic vaccine in a chronic HBV mouse model | en |
dc.type | Thesis | |
dc.date.schoolyear | 109-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 楊宏志(Hung-Chih Yang),陶秘華(Mi-Hua Tao),許秉寧(Ping-Ning Hsu),黃麗蓉(Li-Rung Huang) | |
dc.subject.keyword | 慢性B型肝炎,免疫治療,先天性免疫,骨髓系細胞,HBV X蛋白, | zh_TW |
dc.subject.keyword | Chronic Hepatitis B,Immune therapy,Hepatic innate immunity,myeloid cell,HBV X protein, | en |
dc.relation.page | 83 | |
dc.identifier.doi | 10.6342/NTU202004254 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-10-15 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1210202013475600.pdf 目前未授權公開取用 | 2.29 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。